title: Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure.
abstract: Selegiline is a centrally acting sympatholytic agent with neuroprotective properties. It also has been shown to promote sympathetic reinnervation after sympathectomy. These actions of selegiline may be beneficial in heart failure that is characterized by increased sympathetic nervous activity and functional sympathetic denervation. Twenty-seven rabbits with rapid cardiac pacing (360 beats/min, 8 wk) and twenty-three rabbits without pacing were randomly assigned to receive selegiline (1 mg/day, 8 wk) or placebo. Rapid pacing increased plasma norepinephrine (NE) and decreased left ventricular fractional shortening, baroreflex sensitivity, cardiac sympathetic nerve terminal profiles, cardiac NE uptake activity, and myocardial beta-adrenoceptor density. Selegiline administration to animals with rapid ventricular pacing attenuated the increase in plasma NE and decreases in fractional shortening, baroreflex sensitivity, sympathetic nerve profiles, NE uptake activity and beta-adrenoceptor density. Thus selegiline appears to exert a sympatholytic and cardiac neuroprotective effect in pacing-induced cardiomyopathy. The effects are potentially beneficial because selegiline not only improves cardiac function but also increases baroreflex sensitivity in heart failure.
authors.affiliation: Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA.
authors.forename: J
authors.initials: J
authors.lastname: Shite
authors.forename: E
authors.initials: E
authors.lastname: Dong
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: S Y
authors.initials: SY
authors.lastname: Stevens
authors.forename: C S
authors.initials: CS
authors.lastname: Liang
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D017704:Baroreflex / Q000187:drug effects; D001665:Binding Sites; D002304:Cardiac Pacing, Artificial; D004195:Disease Models, Animal; D004452:Echocardiography; D006321:Heart / Q000187:drug effects / Q000294:innervation*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D007150:Immunohistochemistry; D007545:Isoproterenol / Q000494:pharmacology; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009638:Norepinephrine / Q000097:blood / Q000493:pharmacokinetics; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000378:metabolism; D012642:Selegiline / Q000494:pharmacology*; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000378:metabolism; D013565:Sympatholytics / Q000494:pharmacology
chemical_list: D018696:Neuroprotective Agents; D011943:Receptors, Adrenergic, beta; D013565:Sympatholytics; D012642:Selegiline; D007545:Isoproterenol; D009638:Norepinephrine